PR Newswire | Jun 3, 2021 09:01AM EDT

Industry Conferences

06/03 08:00 CDT

Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences NAPLES, Fla., June 3, 2021

NAPLES, Fla., June 3, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer patients, and MagicMed Industries ("MagicMed"), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, today announced that David Johnson, Chairman and Chief Executive Officer of Enveric, and Dr. Joseph Tucker, Chief Executive Officer of MagicMed, will be participating in the following investor and industry conferences in June.

On May 24, 2021, Enveric announced a definitive agreement to acquire MagicMed. In June, the senior leadership teams of Enveric and MagicMed along with the MagicMed research and development team will participate in several investor and industry conferences.

Benzinga Capital ConferenceDr. Joseph Tucker, President and CEO of MagicMedFriday, June 4th at 9:50 a.m. ETRegistration: https://www.benzinga.com/events/cannabis/virtual/

LD Micro Invitational XIDavid Johnson, Chairman and CEO of EnvericTuesday, June 8th at 2:30 p.m. ETRegistration: https://ldmicrojune2021.mysequire.com

Emerging Growth ConferenceDavid Johnson, Chairman and CEO of EnvericWednesday, June 9th at 12:00 p.m. ETRegistration: https://goto.webcasts.com/starthere.jsp?ei=1469230&tp_key=f8b5116237&sti=envb

Bio Digital ConferenceDr. Joseph Tucker, President and CEO of MagicMedJune 10th-11th and June 14th-18thRegistration: https://www.bio.org/events/bio-digital

H. C. Wainwright Conference: Psychedelics in Psychiatry and BeyondDr. Joseph Tucker, President and CEO of MagicMedPanel: Drug Discovery and Development of Psychoactive Agents for Psychiatry and BeyondThursday, June 17th at 12:00 p.m. ETRegistration: https://hcwevents.com/psychedelics/

Psychedelic Opportunity SummitDr. Joseph Tucker, President and CEO of MagicMedTuesday, June 22nd at 3:15 p.m. ETPanel: The Power of Derivative Molecules for Treating Brain HealthRegistration: https://momentumevents.com/psychedelicevent/agenda/

For more information regarding each conference, or to schedule a one-on-one meeting with Enveric and MagicMed management, please visit the sponsor's conference website or contact KCSA Strategic Communications at EnvericBio@kcsa.com.

About Enveric Biosciences

Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel naturally occurring medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.

About MagicMed

MagicMed Industries intends to partner with pharmaceutical and other companies to develop and commercialize psychedelic-derived pharmaceutical candidates. MagicMed's psychedelic derivatives library, the Psybrary(tm), is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the Psybrary(tm) is on psilocybin and DMT derivatives, and it is then expected to be expanded to other psychedelics such as MDMA, LSD, mescaline, and ibogaine. For more information, please visit https://www.magicmedindustries.com/.

Enveric Investor ContactsValter Pinto / Allison SossKCSA Strategic Communications212.896.1254 / 212.896.1267valter@kcsa.com / asoss@kcsa.com

Enveric Media ContactsCaitlin Kasunich / Raquel ConaKCSA Strategic Communications212.896.1241 / 516.779.2630ckasunich@kcsa.com / rcona@kcsa.com

MagicMed Industries ContactNatalie DolphinDirector of Marketingndolphin@magicmedindustries.com

View original content: http://www.prnewswire.com/news-releases/enveric-biosciences-and-magicmed-to-participate-in-june-2021-investor-and-industry-conferences-301304765.html

SOURCE Enveric Biosciences